A compound having the following formula: wherein: R 1 represents: • an aryl(C 1 -C 6)alkyl group; • an aryl(C 2 -C 6)alkenyl group; • an aryl group; • a heteroaryl group; • a heterocycloalkyl group; • a cycloalkyl group; or • a -QR group, with Q being O or S, and R being alkyl, aryl or aralkyl; said group being optionally substituted by at least one -OH, halogen, (C 1 -C 6)alkyl optionally substituted by one or more fluorine atoms, or (C 1 -C 6)alkyloxy; Z represents CR 2; R 2 represents H, a (C 1 -C 4)alkyl or a phenyl group; X and Y are N and CR 6 respectively; R 6 is H or a (C 1 -C 4)alkyl group; n is 3, 4, 5, or 6; R 3 and R 4: • represent independently a radical selected from a hydrogen atom, a (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aryl(C 1 -C 6)alkyl, said radical being optionally substituted by at least one substituent selected from the group consisting of a hydroxy, a (C 1 -C 6)alkyl, a (C 1 -C 6)alcoxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl; or • form, together with the nitrogen to which they are bound, a nitrogen-based heterocycloalkyl, said nitrogen-based heterocycloalkyl being optionally substituted by at least one substituent selected from the group consisting of a hydroxy, oxo, (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aryl(C 1 -C 6)alkyl, hydroxy(C 1 -C 6)alkyl, and said nitrogen-based heterocycloalkyl being optionally fused with at least one 5-14 membered ring selected from aryl and heteroaryl; each of R 5 represents independently H, OH, or a (C 1 -C 4)alkyl group; a stereoisomer, a solvate or any pharmaceutical salt thereof. R 1 represents: • an aryl(C 1 -C 6)alkyl group; • an aryl(C 2 -C 6)alkenyl group; • an aryl group; • a heteroaryl group; • a heterocycloalkyl group; • a cycloalkyl group; or • a -QR group, with Q being O or S, and R being alkyl, aryl or aralkyl; said group being optionally substituted by at least one -OH, halogen, (C 1 -C 6)alkyl optionally substituted by one or more fluorine atoms, or (C 1 -C 6)alkyloxy; • an aryl(C 1 -C 6)alkyl group; • an aryl(C 2 -C 6)alkenyl group; • an aryl group; • a heteroaryl group; • a heterocycloalkyl group; • a cycloalkyl group; or • a -QR group, with Q being O or S, and R being alkyl, aryl or aralkyl; said group being optionally substituted by at least one -OH, halogen, (C 1 -C 6)alkyl optionally substituted by one or more fluorine atoms, or (C 1 -C 6)alkyloxy; Z represents CR 2; R 2 represents H, a (C 1 -C 4)alkyl or a phenyl group; X and Y are N and CR 6 respectively; R 6 is H or a (C 1 -C 4)alkyl group; n is 3, 4, 5, or 6; R 3 and R 4: • represent independently a radical selected from a hydrogen atom, a (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aryl(C 1 -C 6)alkyl, • represent independently a radical selected from a hydrogen atom, a (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aryl(C 1 -C 6)alkyl, said radical being optionally substituted by at least one substituent selected from the group consisting of a hydroxy, a (C 1 -C 6)alkyl, a (C 1 -C 6)alcoxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl; or • form, together with the nitrogen to which they are bound, a nitrogen-based heterocycloalkyl, • form, together with the nitrogen to which they are bound, a nitrogen-based heterocycloalkyl, said nitrogen-based heterocycloalkyl being optionally substituted by at least one substituent selected from the group consisting of a hydroxy, oxo, (C 1 -C 6)alkyl, (C 2 -C 6)alkenyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aryl(C 1 -C 6)alkyl, hydroxy(C 1 -C 6)alkyl, and said nitrogen-based heterocycloalkyl being optionally fused with at least one 5-14 membered ring selected from aryl and heteroaryl; each of R 5 represents independently H, OH, or a (C 1 -C 4)alkyl group; a stereoisomer, a solvate or any pharmaceutical salt thereof.